Design and Optimization of Renin Inhibitors: Orally Bioavailable Alkyl Amines
Overview
Authors
Affiliations
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension.
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
Jia L, Simpson R, Yuan J, Xu Z, Zhao W, Cacatian S ACS Med Chem Lett. 2014; 2(10):747-51.
PMID: 24900262 PMC: 4018089. DOI: 10.1021/ml200137x.
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.
Siragy H Vasc Health Risk Manag. 2011; 7:297-313.
PMID: 21633727 PMC: 3104607. DOI: 10.2147/VHRM.S15541.